Figures & data
Figure 1 Absolute change in performance time for the responders (n = 5) and non-responders (n = 5) comparing acute (ACU) versus acute placebo (PLC-A) supplementation trials. Performance was significantly different in the ACU versus PLC-A (P < 0.05). Each line represents a different swimmer.
![](/cms/asset/d6ee32a6-84b7-4fe5-85b7-f2ef731687b1/rssn_a_12129739_f0001_oc.jpg)
Table 1 Physical characteristics (mean ± SEM) of both the 5 responders and 5 non-responders
Figure 2 Post-trial lactate concentrations (mmol/L) of responders and non-responders. aSignificantly different (P < 0.05) from acute placebo trial (PLC-A). bSignificantly different (P < 0.05) from non-responders in the acute (ACU) trial. cSignificantly different (P < 0.05) from non-responders in the chronic (CHR) trial. Values are Mean ± SEM.
![](/cms/asset/5116c59e-167a-483c-9187-1ddfd63969a2/rssn_a_12129739_f0002_oc.jpg)
Figure 3 Base excess (BE) (mmol/L) at basal, post-ingestion, and post-trial time points for the acute placebo (PLC-A), acute (ACU), chronic (CHR) and chronic placebo (PLC-C) trials. aSignificant difference during post-ingestion (P < 0.05) between ACU and PLC-A. bSignificant difference during post-ingestion (P < 0.05) between CHR and PLC-C. cSignificant difference during basal (P < 0.05) between CHR and ACU. Significant time effects (P < 0.05) basal to post-ingestion in ACU and PLC-C. Significant time effects (P < 0.05) post-ingestion to post-trial in ACU, CHR, and PLC-C. Values are Mean ± SEM.
![](/cms/asset/c373d67a-31ae-438a-8c86-c0b6169e499b/rssn_a_12129739_f0003_oc.jpg)
Figure 4 Bicarbonate concentration (mmol/L) at basal, post-ingestion, and post-trial time points for the acute placebo (PLC-A), acute (ACU), chronic (CHR) and chronic placebo (PLC-C) trials. aSignificant difference during post-ingestion (P < 0.05) between ACU and PLC-A. bSignificant difference during post-ingestion (P < 0.05) between CHR and PLC-C. Significant time effects (P < 0.05) basal to post-ingestion in ACU and PLC-C. Significant time effects (P < 0.05) post-ingestion to post-trial in ACU, CHR, and PLC-C. Values are Mean ± SEM.
![](/cms/asset/f579d804-c0cf-4aef-8313-62195840ea50/rssn_a_12129739_f0004_oc.jpg)
Figure 5 Blood pH at basal, post-ingestion, and post-trial time points for the acute placebo (PLC-A), acute (ACU), chronic (CHR) and chronic placebo (PLC-C) trials. Significant time effects (P < 0.05) from basal to post-ingestion. Trend to significance (P = 0.06) during post-ingestion between ACU and PLC-A. Values are Mean ± SEM.
![](/cms/asset/167700c4-d1f3-40b5-ae05-18c09c88ff78/rssn_a_12129739_f0005_oc.jpg)